Agios Pharmaceuticals Inc AGIO:NASDAQ

RT Quote | NASDAQ | USD
Last | 02/26/21 EST
47.44quote price arrow down-2.85 (-5.67%)
Volume
1,124,383
52 week range
27.77 - 58.93

...

Loading . . .

KEY STATS

  • Open47.63
  • Day High49.85
  • Day Low46.57
  • Prev Close47.44
  • 52 Week High58.93
  • 52 Week High Date02/11/21
  • 52 Week Low27.77
  • 52 Week Low Date03/18/20
  • Market Cap3.29B
  • Shares Out69.36M
  • 10 Day Average Volume0.72M
  • Dividend-
  • Dividend Yield-
  • Beta1.62
  • 1 Year % Change6.39

RATIOS/PROFITABILITY

  • EPS (TTM)-4.74
  • P/E (TTM)-10.00
  • Fwd P/E (NTM)-15.20
  • EBITDA (MRQ)-306.165M
  • ROE (MRQ)-62.95%
  • Revenue (MRQ)203.20M
  • Gross Margin (MRQ)98.62%
  • Net Margin (MRQ)-161.11%
  • Debt To Equity (MRQ)0.16%

EVENTS

  • Earnings Date04/28/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Agios Pharmaceuticals Inc News

There is no recent news for this security.

Latest AGIO News From Our Partners

QUOTE FINDER

Profile

MORE
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881...
David Schenkein M.D.
Chairman
Jacqualyn Fouse Ph.D.
Chief Executive Officer
Jonathan Biller
Chief Financial Officer
Address
88 Sidney St
Cambridge, MA
02139-4137
United States